Axxcess Wealth Management LLC Grows Holdings in Sanofi (NASDAQ:SNY)

Axxcess Wealth Management LLC raised its position in Sanofi (NASDAQ:SNY - Free Report) by 130.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,234 shares of the company's stock after purchasing an additional 5,794 shares during the period. Axxcess Wealth Management LLC's holdings in Sanofi were worth $568,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Bank of America Corp DE lifted its holdings in Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after purchasing an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Boston Partners lifted its holdings in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after purchasing an additional 369,530 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.8%

SNY traded up $0.40 on Wednesday, reaching $48.52. 1,615,775 shares of the company's stock were exchanged, compared to its average volume of 2,322,424. The company's 50 day moving average is $49.83 and its 200-day moving average is $52.10. The company has a market cap of $118.99 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 1.11 and a beta of 0.48. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the company earned $1.78 earnings per share. Sanofi's revenue for the quarter was down 11.0% on a year-over-year basis. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

SNY has been the topic of several recent analyst reports. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a report on Monday, June 2nd. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of "Buy" and an average target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.